Document:

<PAGE>   1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                                  EXHIBIT 10.118

                              TERMINATION AGREEMENT

        THIS TERMINATION AGREEMENT (the "Agreement") is made and entered into
effective as of December 31, 1999 (the "Effective Date"), by and between AXYS
PHARMACEUTICALS, INC. ("AXYS"), a Delaware corporation, formerly known as Arris
Pharmaceutical Corporation, having a place of business at 180 Kimball Way, South
San Francisco, CA 94080, and BRISTOL-MYERS SQUIBB COMPANY ("BMS"), a Delaware
corporation having a place of business at Route 206 and Province Line Road,
Princeton, NJ 08543-4000. Axys and BMS may be referred to herein individually as
a "Party" or, collectively, as the "Parties."

                                    RECITALS

        A. The Parties are parties to that certain Collaborative Research and
License Agreement entered into by Arris Pharmaceutical Corporation and BMS dated
October 24, 1997 (the "Collaboration Agreement"), and they now wish to terminate
the Collaboration Agreement as provided in this Agreement.

        B. Concurrent with the execution of this Agreement, and in partial
consideration for terminating the Collaboration Agreement pursuant to the terms
of this Agreement and the surviving rights and obligations set forth under the
Collaboration Agreement, BMS and Axys Advanced Technologies, Inc.(a subsidiary
of Axys) are entering into a Combinatorial Chemistry Agreement (the
"Combinatorial Chemistry Agreement").

NOW THEREFORE, the Parties agree as follows:

        1. DEFINITIONS. Any capitalized terms used in this Agreement not defined
herein shall have the meanings as defined in the Collaboration Agreement.

        2. TERMINATION OF AGREEMENT. The Parties agree that Collaboration
Agreement is hereby terminated, and that such termination shall be deemed to be
a termination by BMS pursuant to the provisions of Section 10.3(i) of the
Collaboration Agreement. All the consequences, rights and obligations of the
Parties under the Collaboration Agreement based on a termination pursuant to the
provisions of Section 10.3(i) of the Collaboration Agreement shall apply, except
as otherwise provided in this Agreement. BMS is hereby deemed automatically to
have granted to Axys as of the Effective Date all the rights that are to be
granted to Axys under Sections 10.5(b) and 10.5(d) of the Collaboration
Agreement.

        3. TERMINATION OF OBLIGATIONS. The Parties agree that any and all of the
following obligations are deemed to have terminated and ceased as of [ * ]: (a)
all the Parties' obligations to conduct any further Research work under the
Collaboration Agreement; and (b) BMS's obligation to fund the Research pursuant
to Section 2.5 of the Collaboration Agreement. Further,

                                       1.
<PAGE>   2

the Parties agree that, notwithstanding the provisions of Sections 2.9 and
10.3(i) of the Collaboration Agreement, [ * ] shall have no obligation to [ * ],
and any such obligations is hereby waived and terminated.

        4. MISCELLANEOUS PROVISIONS.

            (a) ASSIGNMENTS. Except as expressly provided herein, neither this
Agreement nor any interest hereunder nor any surviving right or obligation under
the Collaboration Agreement shall be assignable by a Party without the prior
written consent of the other; provided, however, that a Party may assign this
Agreement and any surviving rights and obligations under the Collaboration
Agreement to any Affiliate or to any successor in interest by way of merger,
acquisition or sale of all or substantially all of its assets in a manner such
that the assignee shall be liable and responsible for the performance and
observance of all such Party's duties and obligations hereunder and thereunder.
This Agreement and any surviving rights and obligations under the Collaboration
Agreement and the Collaboration Agreement shall be binding upon the successors
and permitted assigns of the Parties. Any assignment not in accordance with this
Section 4(a) shall be void.

            (b) ENTIRE AGREEMENT OF THE PARTIES; AMENDMENTS. This Agreement, the
surviving provisions of the Collaboration Agreement, and the Combinatorial
Chemistry Agreement constitute and contain the entire understanding and
agreement of the Parties respecting the subject matter hereof and cancel and
supersede any and all prior negotiations, correspondence, understandings and
agreements between the Parties, whether oral or written, regarding such subject
matter. No waiver, modification or amendment of any provision of this Agreement,
the surviving provisions of the Collaboration Agreement, and the Combinatorial
Chemistry Agreement shall be valid or effective unless made in writing and
signed by a duly authorized officer of each Party.

            (c) APPLICABLE LAW. This Agreement shall be governed by and
interpreted in accordance with the laws of the State of New York, USA,
applicable to contracts entered into and to be performed wholly within the State
of New York, excluding conflict of laws principles.

            (d) WAIVER. A waiver by either Party of any of the terms and
conditions of this Agreement or the surviving provisions of the Collaboration
Agreement in any instance shall not be deemed or construed to be a waiver of
such term or condition for the future or of any subsequent breach hereof. All
rights, remedies, undertakings, obligations and agreements contained in this
Agreement the surviving provisions of the Collaboration Agreement shall be
cumulative and none of them shall be in limitation of any other remedy, right,
undertaking, obligation or agreement of either Party.

            (e) COUNTERPARTS. This Agreement may be executed simultaneously in
any number of counterparts, any one of which need not contain the signature of
more than one Party but all such counterparts taken together shall constitute
one and the same agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       2.
<PAGE>   3

        IN WITNESS WHEREOF, the Parties have caused this Agreement to be
executed by their respective duly authorized officers as of the day and year
first above written, each copy of which shall for all purposes be deemed to be
an original.

AXYS PHARMACEUTICALS, INC.                 BRISTOL-MYERS SQUIBB COMPANY

By:  /s/ John P. Walker                    By  /s/ William H. Koster, Ph.D.
    ---------------------------------         ----------------------------------
Name:   John P. Walker                     Name:  William H. Koster, Ph.D.
      -------------------------------           --------------------------------

Title:  Chairman                           Title: Senior Vice President, Applied
       ------------------------------             Discovery & Exploratory
                                                  Development
Date:   1/14/00                            Date:
      -------------------------------           --------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       3.<PAGE>   1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                                  EXHIBIT 10.119

                          THIRD AMENDMENT TO AGREEMENT

        This is the third amendment to the Research Collaboration and License
Agreement between MERCK & CO., INC., a corporation organized and existing under
the laws of New Jersey ("MERCK") and ARRIS PHARMACEUTICAL CORPORATION, a
corporation organized and existing under the laws of Delaware, now known as Axys
Pharmaceuticals, Inc. ("Axys") made as of November 6, 1996 (the "Agreement").
The purpose of this third amendment is to extend the Research Program Term
through November 5, 2000, and to increase the number of FTEs for the period
September 1, 1999 through November 5, 2000.

        1. In accordance with the provisions of Section 2.8 and Section 5.2(d)
of the Agreement and subject to MERCK's right to terminate the Research Program
and the Agreement in accordance with Section 8.2, the Research Program Term is
extended through November 5, 2000, and the parties agree that [ * ] FTEs will be
required during the period September 1, 1999 through November 5, 2000. The FTEs
for the period September 1, 1999 through November 5, 1999 shall be payable at an
annual rate of [ * ] per FTE. The FTEs for the period November 6, 1999 through
November 5, 2000 shall be payable at an annual rate of [ * ] per FTE.

        2. Attachment 2.1 setting forth the Research Program is hereby amended
to include the additional research work set forth on the attachment to this
third amendment.

        3. Capitalized terms used and not otherwise defined herein shall have
the respective meanings set forth in the Agreement. The Agreement, together with
the first amendment dated February 9, 1998, the second amendment dated November
5, 1998 and this third amendment contain the entire understanding of the parties
with respect to their subject matter. All express or implied agreements and
understandings, either oral or written, heretofore made are expressly merged in
and made a part of the Agreement as amended by the first, second and third
amendments. All other terms and conditions of the Agreement, as amended,
continue in full force and effect. The Agreement and its amendments may be
amended, or any term thereof modified, only by a written instrument duly
executed by both parties hereto.

        IN WITNESS WHEREOF, the parties have entered into this Amendment as of
18 November, 1999.

MERCK & CO., INC.                                  AXYS PHARMACEUTICAL, INC.

BY: /s/ Roger M. Perlmutter, M.D., Ph.D.           BY: /s/ John P. Walker
    ------------------------------------               -------------------------
    Roger M. Perlmutter, M.D., Ph.D.                   John P. Walker
    Executive Vice President                           Chairman
    Worldwide Basic Research                           Chief Executive Officer
    And Preclinical Development

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       1.
<PAGE>   2

                                                                  Attachment 2.1
                                                                Research Program

                                 ATTACHMENT 2.1

                                RESEARCH PROGRAM

        The work outlined below, initiated [ * ], will be completed by [ * ].

        1. [ * ]

           [ * ]

        2. [ * ]

           [ * ]

        3. [ * ]

           [ * ]

        4. [ * ]

        [ * ]

        5. [ * ]

        [ * ]

        6. [ * ]

           [ * ]

        7. [ * ]

        a. [ * ]

        b. [ * ]

        c. [ * ]

        d. [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       1.
<PAGE>   3

                                                                  Attachment 2.1
                                                                Research Program

                                   APPENDIX A

                                      [ * ]

        [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       2.
<PAGE>   4

                                                                  Attachment 2.1
                                                                Research Program

                                   APPENDIX B

                                      [ * ]

        [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       3.
<PAGE>   5

                                                                  Attachment 2.1
                                                                Research Program

                                   APPENDIX C

                                      [ * ]

        [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       4.
<PAGE>   6

                                                                  Attachment 2.1
                                                                Research Program

                                   APPENDIX D

                                      [ * ]

        [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       5.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]